Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
News
Doxorubicin, ifosfamide combination touted for advanced sarcomas
Publish date:
March 13, 2014
EXPERT ANALYSIS FROM SARCOMA AND GIST 2014
mzoler@frontlinemedcom.com
On Twitter
@mitchelzoler
Pages
« first
1
2
Recommended Reading
Third drug approved for metastatic, treatment-resistant GIST
MDedge Hematology and Oncology
BEAM technology shines a light on drug resistance mutations in GIST
MDedge Hematology and Oncology
Rhabdomyosarcoma in an adult with HIV
MDedge Hematology and Oncology
IMRT bests conventional radiation for soft-tissue sarcomas of the extremities
MDedge Hematology and Oncology
Ridaforolimus offers moderate maintenance benefit in advanced sarcoma
MDedge Hematology and Oncology
Pazopanib shows promise as pediatric sarcoma therapy
MDedge Hematology and Oncology
Liquid biopsies may solve GIST biopsy problem
MDedge Hematology and Oncology
Role for GIST genotyping stirs controversy
MDedge Hematology and Oncology
Europe’s latest sarcoma guidelines increase emphasis on genetic profiling
MDedge Hematology and Oncology
Some consider denosumab standard treatment for unresectable giant cell tumor of bone
MDedge Hematology and Oncology
Sarcoma & GIST
All Specialties
